Drug Type Small molecule drug |
Synonyms Quinidine gluconate (USP), Duraquin, Quinact + [3] |
Mechanism SCNA blockers(Sodium channel alpha subunit blockers), α-adrenergic receptor antagonists(Alpha adrenergic receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseWithdrawn |
First Approval Date US (12 Jul 1950), |
Regulation- |
Molecular FormulaC26H36N2O9 |
InChIKeyXHKUDCCTVQUHJQ-LCYSNFERSA-N |
CAS Registry7054-25-3 |
Start Date06 Oct 2022 |
Sponsor / Collaborator |
Start Date01 Oct 2022 |
Sponsor / Collaborator |
Start Date19 Sep 2022 |
Sponsor / Collaborator- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00642 | Quinidine Gluconate | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Arrhythmias, Cardiac | US | 12 Jul 1950 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Not Applicable | - | hmyxxellob(hsvluhxwix): HR = 0.74 (95% CI, 0.22 - 2.48), P-Value = 0.62 | - | 03 Sep 2019 | |||
quinidine | |||||||
Not Applicable | KCNT1 gene mutation | 1 | wrsdquilay(tzrpkvmwtm) = qrknlznhle hzvgricnvt (uehxbzpbqj ) | Positive | 05 Oct 2018 | ||
Not Applicable | - | - | oapxqjgqzm(ikhukmcbkd) = xlomxmzouy hccmuqrrkr (ufdsbwmlsx, ± 12.4) | - | 12 Jun 2002 |